Abstract:2576 Background: Tumor microenvironment (TME) heterogeneity leads to the discrepancy of survival prognosis and clinical treatment response for HCC patients. Although the documented molecular subtypes moderately describe the TME heterogeneity and characteristics, their clinical application is constrained by several issues. Methods: We integrated three single-cell datasets from 39 HCC patients to describe the TME landscape and identified prognosis-related cell subclusters. Unsupervised clustering of subcluster-specific markers (SSMs) was performed to generate transcriptomic subtypes. The predictive value of these molecular subtypes for prognosis and treatment response was explored in multiple external HCC cohorts and Xiangya real-world HCC cohort with patients who received immune checkpoint blockade (ICB) therapy. Cancer stemness was estimated using bioinformatic methods and in vivo and in vitro experiments. The features of TME were further validated using single-cell RNA-seq and immune repertoire sequencing, mass cytometry (CyTOF) and multiplex immunofluorescence (mIF). Ultimately, we constructed prognosis-related score (PRS)based on machine learning algorithm, and identified the potential therapeutic targets and agents for high-PRS patients. Results: The comprehensive single-cell analysis provided a high-resolution depiction of TME heterogeneity in HCC and confirmed 6 cell subclusters of prognostic relevance. Five transcriptomic subtypes were constructed using SSMs, which possessed different clinical prognosis, stemness characteristics, immune landscape and therapeutic responses. Class 1 indicated an inflamed phenotype with better clinical outcomes, while Class 2 and class 4 demonstrated immune-deserted phenotypes lacking T cells infiltration. Class 5 and class 3 indicated inhibitory tumor immune microenvironment enriched regulatory T cells and suppressive immune checkpoints. Multiple therapeutic cohorts suggested that Class 5 and class 3 were sensitive to ICB and targeted therapy, while Class 1 and Class 2 were more responsive to transcatheter arterial chemoembolization treatment (TACE). Class 4 displayed resistant to all conventional HCC therapies. The PRS performed well in prognostic prediction in multiple HCC cohorts. Four potential therapeutic agents and four targets were further identified for high-PRS HCC patients. Conclusions: Our study generated a clinically valid molecular classification, thereby providing guidance for precision medicine in HCC patients.

Clustering of Transcriptomic Data for the Identification of Cancer Subtypes

Identification of cancer subtypes from single-cell RNA-seq data using a consensus clustering method

A Clustering Approach to Integrative Analysis of Multiomic Cancer Data

Subtype-DCC: decoupled contrastive clustering method for cancer subtype identification based on multi-omics data

Clustering cancer gene expression data: a comparative study

A clustering approach to integrative analyses of multiomic cancer data

Identification of Genomic Aberrations in Cancer Subclones from Heterogeneous Tumor Samples

Identification of Molecular Subtypes for Integrated Multi-Omics Analysis for Use in Guiding Precision Medicine in Hepatocellular Carcinoma.

Identifying and Analyzing Different Cancer Subtypes Using RNA-seq Data of Blood Platelets.

Cancer Subtyping by Improved Transcriptomic Features Using Vector Quantized Variational Autoencoder

Identification of clear cell renal cell carcinoma subtypes by integrating radiomics and transcriptomics

Identifying cancer subtypes in glioblastoma by combining genomic, transcriptomic and epigenomic data

Learning vector quantized representation for cancer subtypes identification

Outcome-guided Bayesian clustering for disease subtype discovery using high-dimensional transcriptomic data

Cancer Subtyping via Embedded Unsupervised Learning on Transcriptomics Data

Archetypal solution spaces for clustering gene expression datasets in identification of cancer subtypes

Multi-Omics Data Fusion for Cancer Molecular Subtyping Using Sparse Canonical Correlation Analysis

Supervised Graph Clustering for Cancer Subtyping Based on Survival Analysis and Integration of Multi-Omic Tumor Data

Tumor Heterogeneity in Gastrointestinal Cancer Based on Multimodal Data Analysis

Integrative Analysis of RNA Expression Data Unveils Distinct Cancer Types through Machine Learning Techniques

Cancer subtype identification by multi-omics clustering based on interpretable feature and latent subspace learning